Apeloa Pharmaceutical Co.,Ltd (SHE:000739)
18.11
+0.41 (2.32%)
Apr 8, 2026, 3:04 PM CST
SHE:000739 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 3,786 | 3,662 | 3,581 | 3,553 | 2,610 |
Trading Asset Securities | - | - | - | 0.09 | 14.89 |
Cash & Short-Term Investments | 3,786 | 3,662 | 3,581 | 3,553 | 2,625 |
Cash Growth | 3.41% | 2.26% | 0.78% | 35.35% | 13.61% |
Accounts Receivable | 2,271 | 2,265 | 2,243 | 2,040 | 1,523 |
Other Receivables | 99.96 | 112.26 | 114.46 | 116.28 | 103.74 |
Receivables | 2,371 | 2,378 | 2,421 | 2,156 | 1,626 |
Inventory | 1,602 | 1,860 | 2,083 | 1,802 | 1,250 |
Prepaid Expenses | 7.33 | 4.64 | 26.65 | 20.59 | 13.06 |
Other Current Assets | 112.57 | 282.71 | 256.96 | 249.5 | 267.72 |
Total Current Assets | 7,879 | 8,187 | 8,368 | 7,781 | 5,782 |
Property, Plant & Equipment | 3,583 | 3,775 | 3,564 | 3,406 | 2,588 |
Long-Term Investments | 186.68 | 139.66 | 174.05 | 91.41 | 81.25 |
Goodwill | 20.31 | 20.31 | 20.31 | 20.31 | 20.31 |
Other Intangible Assets | 300.74 | 314.61 | 319.8 | 338.93 | 346.05 |
Long-Term Deferred Tax Assets | 234.7 | 227.66 | 247.4 | 270.29 | 47.58 |
Long-Term Deferred Charges | 83.57 | 15.77 | 20.57 | 66.21 | 46.76 |
Other Long-Term Assets | 25.4 | 45.83 | 53.75 | 47.15 | 133.22 |
Total Assets | 12,318 | 12,729 | 12,768 | 12,021 | 9,045 |
Accounts Payable | 3,382 | 3,633 | 4,127 | 4,311 | 2,623 |
Accrued Expenses | 258.26 | 251.62 | 226.43 | 202.82 | 221.62 |
Short-Term Debt | 1,027 | 814.03 | 807.8 | 562.81 | 332.47 |
Current Portion of Long-Term Debt | 1 | 5 | 81.34 | 0.4 | 0.2 |
Current Portion of Leases | 5.36 | 6.61 | 7.98 | 8.65 | 13.77 |
Current Income Taxes Payable | 121.17 | 92.33 | 77.04 | 80.59 | 120.56 |
Current Unearned Revenue | 185.89 | 514.33 | 430.37 | 458.26 | 302.4 |
Other Current Liabilities | 384.67 | 425.26 | 550.05 | 402.44 | 165.8 |
Total Current Liabilities | 5,365 | 5,743 | 6,308 | 6,027 | 3,779 |
Long-Term Debt | 468.3 | 70.05 | 18.71 | 249.62 | 104.94 |
Long-Term Leases | 18.91 | 13.78 | 4.47 | 15.81 | 22.95 |
Long-Term Unearned Revenue | 51.85 | 31.69 | 30.62 | 15.12 | 1.17 |
Long-Term Deferred Tax Liabilities | 67.7 | 84.98 | 103.71 | 122.96 | 4.25 |
Other Long-Term Liabilities | - | 36 | 72 | 72 | 72 |
Total Liabilities | 5,972 | 5,979 | 6,537 | 6,502 | 3,985 |
Common Stock | 1,158 | 1,169 | 1,179 | 1,179 | 1,179 |
Additional Paid-In Capital | 104.79 | 247 | 438.01 | 438.01 | 438.01 |
Retained Earnings | 5,558 | 5,481 | 4,804 | 4,096 | 3,443 |
Treasury Stock | -482.06 | -153.09 | -200.2 | -200.2 | - |
Comprehensive Income & Other | -0.96 | -2.02 | 2.01 | -0.79 | 0.43 |
Total Common Equity | 6,338 | 6,742 | 6,223 | 5,512 | 5,060 |
Minority Interest | 7.92 | 7.92 | 7.69 | 7.35 | - |
Shareholders' Equity | 6,346 | 6,750 | 6,230 | 5,519 | 5,060 |
Total Liabilities & Equity | 12,318 | 12,729 | 12,768 | 12,021 | 9,045 |
Total Debt | 1,520 | 909.47 | 920.3 | 837.3 | 474.33 |
Net Cash (Debt) | 2,266 | 2,752 | 2,660 | 2,716 | 2,151 |
Net Cash Growth | -17.66% | 3.45% | -2.04% | 26.27% | 8.61% |
Net Cash Per Share | 1.96 | 2.37 | 2.28 | 2.31 | 1.82 |
Filing Date Shares Outstanding | 1,126 | 1,158 | 1,169 | 1,169 | 1,179 |
Total Common Shares Outstanding | 1,128 | 1,158 | 1,169 | 1,169 | 1,179 |
Working Capital | 2,514 | 2,444 | 2,060 | 1,755 | 2,003 |
Book Value Per Share | 5.62 | 5.82 | 5.32 | 4.71 | 4.29 |
Tangible Book Value | 6,017 | 6,407 | 5,883 | 5,153 | 4,694 |
Tangible Book Value Per Share | 5.34 | 5.53 | 5.03 | 4.41 | 3.98 |
Buildings | 2,032 | 1,991 | 1,743 | 1,743 | 1,474 |
Machinery | 5,162 | 4,767 | 4,398 | 4,126 | 2,903 |
Construction In Progress | 244.11 | 407.48 | 545.85 | 311.4 | 710.22 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.